Golidocitinib and chidamide for refractory or relapsed peripheral T‐cell lymphoma: A preliminary cost‐effectiveness analysis in China
Golidocitinib demonstrates potential cost-effectiveness versus chidamide for r/rPTCL in China. While definitive conclusions await head-to-head trials, these MAIC-adjusted results provide preliminary evidence for resource allocation decisions.
Authors
- Wenwen Du (ORCID: https://orcid.org/0000-0002-9826-8405)
- Yujie Tan
- Wei Xu (ORCID: https://orcid.org/0000-0002-6925-0636)
- Tianyu Jing (ORCID: https://orcid.org/0000-0002-8439-8778)
- Jingkai Zha
- Ke Shi
Institutions
- China Pharmaceutical University (CN)
- Fudan University (CN)
- National Health and Family Planning Commission (CN)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-09-12
- DOI
- https://doi.org/10.1002/bcp.70269
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00